[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559379":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":115,"collaborators":117,"id":127,"slug":128,"hasResults":129,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":129,"sex":135,"minAge":136,"maxAge":20,"enrollmentInfo":137,"targetDuration":20,"studyType":140,"phases":141,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":161},{"fullName":5,"class":6},"University of Zurich","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Elective target volume de-escalation arm","EXPERIMENTAL","Target volume de-escalation",[13],"Radiation: De-escalation of irradiated volume",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","De-escalation of irradiated volume","De-escalation of elective clinical target volumes as recommended by a model-based approach",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Panagiotis Balermpas, MD","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","+41 44 255 35 67","Panagiotis.Balermpas@usz.ch",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},"Debra Lauer, MSc","+41 43 253 28 17","RAO_Akademischesoffice@usz.ch",[35,52,65,76,89,102],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Zurich University Hospital","RECRUITING","Zurich","Canton of Zurich","8091","Switzerland","CH",{"type":44,"coordinates":45},"Point",[46,47],8.55,47.36667,{"lat":47,"lon":46},[50],{"name":51,"role":27,"phone":20,"phoneExt":20,"email":20},"Panagiotis Balermpas",{"facility":53,"status":37,"city":54,"state":20,"zip":20,"country":41,"countryCode":42,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Cantonal Hospital Aarau","Aarau",{"type":44,"coordinates":56},[57,58],8.04422,47.39254,{"lat":58,"lon":57},[61],{"name":62,"role":27,"phone":63,"phoneExt":20,"email":64},"Oliver Riesterer, Prof. Dr. med.","+41 62 838 42 49","oliver.riesterer@ksa.ch",{"facility":66,"status":37,"city":67,"state":20,"zip":20,"country":41,"countryCode":42,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Ospedale Regionale di Bellinzona","Bellinzona",{"type":44,"coordinates":69},[70,71],9.01703,46.19278,{"lat":71,"lon":70},[74],{"name":75,"role":27,"phone":20,"phoneExt":20,"email":20},"Francesco Martucci",{"facility":77,"status":37,"city":78,"state":20,"zip":20,"country":41,"countryCode":42,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Inselspital Bern","Bern",{"type":44,"coordinates":80},[81,82],7.44744,46.94809,{"lat":82,"lon":81},[85],{"name":86,"role":27,"phone":87,"phoneExt":20,"email":88},"Olgun Elicin","+41 31 632 26 32","Olgun.Elicin@insel.ch",{"facility":90,"status":37,"city":91,"state":20,"zip":20,"country":41,"countryCode":42,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Hôpitaux universitaires de Genève","Geneva",{"type":44,"coordinates":93},[94,95],6.14569,46.20222,{"lat":95,"lon":94},[98],{"name":99,"role":27,"phone":100,"phoneExt":20,"email":101},"Sébastien Tran, Dr. med.","+41 22 372 70 90","sebastien.tran@hug.ch",{"facility":103,"status":37,"city":104,"state":20,"zip":20,"country":41,"countryCode":42,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Réseau Hospitalier Neuchâtelois","Neuchâtel",{"type":44,"coordinates":106},[107,108],6.931,46.99179,{"lat":108,"lon":107},[111],{"name":112,"role":27,"phone":113,"phoneExt":20,"email":114},"Sarah Melab, Dr. med.","+41 79 559 44 83","sarah.melab@rhne.ch",{"type":116,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[118,120,122,124,125],{"name":119,"class":6},"Insel Gruppe AG, University Hospital Bern",{"name":121,"class":6},"University Hospital, Geneva",{"name":123,"class":6},"Ospedale Regionale Bellinzona e Valli",{"name":103,"class":6},{"name":126,"class":6},"Kantonsspital Aarau","100559379","phase-2-personalized-volume-deescalated-elective-nodal-irradiation-in-oropharyngeal-head-and-neck-squamous-cell-carcinoma-100559379",false,"NCT06563362","Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell Carcinoma","Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck","DeEscO","Inclusion Criteria:\n\n* Patients with a newly diagnosed (no pre-treatment) squamous cell carcinoma of the oropharynx (i.e. tonsils, base of tongue, oropharyngeal walls, oropharyngeal surface of epiglottis; ICD-10 codes C01, C09, C10), T1-4, N0-3.\n* Treatment with definitive (chemo) radiotherapy planned, with elective irradiation of the lymph nodes.\n* Age ≥ 18 years, no upper age limit.\n* ECOG performance score \\\u003C 3.\n* History\u002Fphysical examination within 30 days prior to study inclusion by head and neck surgeon and\u002For radiation oncologist.\n* FDG-PET scan prior to study inclusion. In case of inability to perform or contra-indication, at least contrast enhanced MRI scan obligatory.\n* Participants need to provide informed consent.\n\nExclusion Criteria:\n\nInclusion Criteria:\n\n* Patients with a newly diagnosed (no pre-treatment) squamous cell carcinoma of the oropharynx (i.e. tonsils, base of tongue, oropharyngeal walls, oropharyngeal surface of epiglottis; ICD-10 codes C01, C09, C10), T1-4, N0-3.\n* Treatment with definitive (chemo) radiotherapy planned, with elective irradiation of the lymph nodes.\n* Age ≥ 18 years, no upper age limit.\n* ECOG performance score \\\u003C 3.\n* History\u002Fphysical examination within 30 days prior to study inclusion by head and neck surgeon and\u002For radiation oncologist.\n* FDG-PET scan prior to study inclusion. In case of inability to perform or contra-indication, at least contrast enhanced MRI scan obligatory.\n* Participants need to provide informed consent.\n\nExclusion Criteria:\n\n* Multilevel primary tumors extending unambiguously beyond the oropharynx into the oral cavity, naso- or hypopharynx\n* Distant metastases detected.\n* Previous surgery, chemotherapy or radiotherapy treatment for other head and neck cancers.\n* Previous surgery in head and neck region affecting the cervical lymphatic system. Dissection of singular lymph nodes for diagnostic purposes before treatment start is allowed.\n* Synchronous or previous malignancies. Exceptions are curatively treated basal cell carcinoma or SCC of the skin, or in situ carcinoma of the cervix uteri, low- or intermediate- risk prostate cancer or breast with a progression-free follow-up time of at least 3 years without any remaining disease burden, or other previous malignancy with a progression-free interval of at least 5 years without any remaining active\u002Fprogressive disease burden regardless whether the treatment is completed or ongoing as a maintenance treatment (e.g. androgen deprivation therapy for prostate cancer).\n* Pregnancy or breast feeding\n* Any severe mental or psychic disorder affecting decision making and ability to provide informed consent.","ALL","18 Years",{"count":138,"type":139},120,"ESTIMATED","INTERVENTIONAL",[142],"PHASE2","Multicentric prospective model-based de-escalation of the elective clinical target volumes (CTV) in radiotherapy of oropharyngeal carcinoma of all stages with the goal to reduce toxicity.\n\nThe study investigates the feasibility of this approach as measured by the number of expected out-of-field recurrencies based on the individual patient's state of disease progression and risk factors",[145],"Oropharynx Cancer",[147,148,149,150,151],"head and neck cancer","radiotherapy","elective CTV","clinical target volume","de-escalation","2026-05-28",{"date":154,"type":155},"2026-06-01","ACTUAL",{"date":157,"type":155},"2025-02-04",{"date":159,"type":139},"2030-02-28",{"name":5,"class":6},6]